STRONG SITE SELECTION LEADS TO SUCCESS

PRA Screens 5 Months Ahead of Schedule
STRONG SITE SELECTION LEADS TO SUCCESS
PRA Screens 5 Months Ahead of Schedule

STUDY DESCRIPTION
A randomized, double-blind, placebo-controlled Phase III study of Study Drug versus placebo for patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatments

<table>
<thead>
<tr>
<th>STUDY DURATION</th>
<th>No. OF CLINICAL SITES</th>
<th>PATIENT POPULATION</th>
<th>TREATMENT PERIOD</th>
</tr>
</thead>
<tbody>
<tr>
<td>33 MONTHS</td>
<td>85</td>
<td>170</td>
<td>6 MONTHS</td>
</tr>
</tbody>
</table>

PRIMARY ENDPOINT
Progression

PRA SERVICES
Full Service

INDICATION
GIST

DRUG CLASS
Multikinase Inhibitor

STUDY PHASE
III

BUSINESS SEGMENT
Product Registration

REGIONS
North America
Western Europe
Central and Eastern Europe
Asia-Pacific

SITUATION
PRA was selected to conduct a global Phase III gastrointestinal stromal tumors (GIST) study for a top 20 large pharmaceutical client.

CHALLENGES
GIST is less specialized in the United States (US) compared to other global locations, and PRA required a large number of US sites to satisfy the regulatory recruitment target. Site identification was also challenging in Europe, as selection occurred during the summer months. While the study’s fixed-price contract included a buffer with extra sites, start-up delays effectively reduced this buffer.

Client communication was particularly complex due to local affiliate involvement in many key decisions. Lack of communication surrounding the client’s expectations for key opinion leaders presented another hurdle for PRA. The client’s training schedule threatened timely site activations.
SOLUTIONS
PRA developed a plan for detailed involvement and close communication from our oncology therapeutic experts. The experts developed tailored site selection strategies based on their knowledge of regional considerations and in-depth understanding of the indication. PRA then collaborated with the client’s steering committee to identify key sites.

RESULTS
PRA’s approach allowed us to screen 5 months ahead of schedule and put the study on track to complete enrollment ahead of initial timelines. The client has since selected PRA as a strategic partner for Product Registration services.